Coologics, a clinical-stage medical device company focused on women’s health, has successfully closed an oversubscribed seed funding round, securing over $3 million in investment. The funding round, led by Prevail and Dream Ventures, saw significant participation from university alumni groups including Ohio State Early Investor Network and Illinois Ventures Illini Angels Program. This substantial investment will accelerate Coologics’ key milestones, including the completion of their ongoing clinical trial, FDA submission, and initial market release of their flagship product, Vlisse.
Company Background and Mission
Coologics is dedicated to supporting female health by addressing underlying issues that affect women daily. The company’s innovative product, Vlisse, represents a potential breakthrough in treating vaginal infections. With strong backing from investors, Coologics is poised to bring this critical solution to market.
Investor Confidence and Future Plans
The oversubscribed funding round demonstrates strong investor confidence in Coologics’ vision and technology. Dr. Kim Langdon, CEO and founder of Coologics, expressed excitement about the investor commitment, stating, “We are beyond excited about the investor commitment to Coologics. The overwhelming interest in our seed round validates the critical need for a more effective treatment for vaginal infections.”
Kerry Lawing, CEO of Prevail Ventures, echoed this sentiment, saying, “Dr. Langdon’s vision and passion for this problem is what excited us the most about Coologics. This market is ripe for innovative solutions like Vlisse.” The investment will enable Coologics to leverage the expertise of its new investors to accelerate growth and deliver impactful solutions to female patients and their clinicians.
Next Steps
The completion of this seed round marks a significant milestone for Coologics as it works towards bringing Vlisse to market. With the secured funding, the company will focus on completing its clinical trial, obtaining FDA approval, and initiating market release. This progress is expected to make a meaningful difference in the treatment of vaginal infections, addressing a critical need in women’s healthcare.
